Inclusion Criteria:

          1. Evidence of IDH1 R132 mutation in tumor tissue (any solid tumor) or circulating tumor
             DNA (cholangiocarcinoma, chondrosarcoma, and glioma) as determined by molecular
             testing routinely performed at a CLIA, ISO/IEC, CAP, or other similarly certified
             laboratory.

          2. Availability of an archived tumor tissue sample. Patients without an available
             archival tumor tissue sample must be discussed with the sponsor's Medical Monitor
             prior to enrollment.

          3. Eastern Cooperative Oncology Group (ECOG) 0-1

          4. At least 18 years of age

          5. Adequate organ function

          6. Ability to swallow capsules or tablets

          7. Ability to comply with outpatient treatment, laboratory monitoring, and required
             clinic visits for the duration of study participation

          8. For cholangiocarcinoma patients, must have adequate biliary drainage (per
             investigator's discretion), with no evidence of ongoing infection.

          9. Willingness of men and women of reproductive potential to observe conventional and
             effective birth control for the duration of treatment and for 3 months following the
             last dose of study treatment. Patients enrolled to Dose Expansion Cohort 4 shall also
             follow cisplatin/gemcitabine contraception duration requirements as determined by
             labels and/or local guidelines.

             Monotherapy Dose Escalation:

         10. A locally advanced or metastatic solid tumor, where standard curative or palliative
             measures are no longer effective or are not considered appropriate or safe in the
             opinion of the investigator.

         11. Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as
             appropriate by tumor type.

         12. Prior IDH1 inhibitor treatment is permitted.

             Monotherapy Dose Expansion Cohort 1:

         13. Histologically or cytologically confirmed diagnosis of advanced or metastatic
             cholangiocarcinoma, following 1 to 2 lines of prior systemic treatment for advanced
             disease. Prior IDH1 inhibitor treatment is not permitted.

         14. Measurable disease as determined by RECIST 1.1.

             Monotherapy Dose Expansion Cohort 2:

         15. A locally advanced or metastatic solid tumor (except for cholangiocarcinoma), where
             standard curative or palliative measures are no longer effective or are not considered
             appropriate or safe in the opinion of the investigator.

         16. Measurable disease as determined by RECIST 1.1 or RANO as appropriate by tumor types.

             Monotherapy Dose Expansion Cohort 3:

         17. A locally advanced or metastatic solid tumor, where standard curative or palliative
             measures are no longer effective or are not considered appropriate or safe in the
             opinion of the investigator.

         18. Non-measurable disease only as determined by RECIST 1.1 or RANO as appropriate by
             tumor type.

             Combination Dose Expansion Cohort 4:

         19. Histologically or cytologically confirmed diagnosis of advanced or metastatic
             cholangiocarcinoma, not eligible for curative resection.

         20. No prior systemic therapy for advanced or metastatic disease with the following
             exceptions:

               -  Patients who received adjuvant chemotherapy are eligible, if the adjuvant therapy
                  was completed at least 6 months prior to the development of advanced or
                  metastatic disease.

               -  Patients who are receiving the first cycle of cisplatin plus gemcitabine as the
                  first line systemic therapy while waiting for results of locally obtained
                  molecule profiling including IDH1 mutational status, are eligible, provided that
                  a radiographic assessment during screening demonstrates the absence of interval
                  disease progression since initiation of chemotherapy treatment, and all other
                  eligibility criteria are met.

         21. Measurable disease as determined by RECIST 1.1.

        Exclusion Criteria:

          1. Had an investigational agent or anticancer therapy within 2 weeks; or investigational
             monoclonal antibody within 4 weeks prior to planned start of LY3410738.

          2. Had major surgery within 4 weeks prior to planned start of LY3410738.

          3. Had radiotherapy with a limited field of radiation for palliation within 7 days of the
             first dose of study treatment, except for patients receiving whole brain radiotherapy,
             which must be completed at least 4 weeks prior to the first dose of study treatment.

          4. Patients with cholangiocarcinoma: underwent hepatic radiation, chemoembolization and
             radiofrequency ablation, radioembolization or other locoregional therapy <4 weeks,
             have history of hepatic encephalopathy of any grade, have ascites requiring
             intervention such as diuretics or paracentesis, have ongoing cholangitis, have mixed
             hepatocellular biliary tract cancer histology

          5. Have active CNS metastases are not eligible. Patients with asymptomatic and treated
             brain metastases may participate provided that they are stable and are not requiring
             steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not
             eligible even if treated.

          6. Have primary CNS tumors are eligible provided that they do not have leptomeningeal
             disease and are on a stable or decreasing steroid dose for 7 days prior to screening.
             Patients with evidence of intracranial hemorrhage either by MRI or CT are not eligible

          7. Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2
             at the time of starting study treatment except for alopecia.

          8. Have clinically significant, uncontrolled cardiac, cardiovascular disease or history
             of myocardial infarction within 6 months prior to planned start of study treatment.

          9. Have active uncontrolled systemic bacterial, viral, fungal or parasitic infection
             (except for fungal nail infection), or other clinically significant active disease
             process which in the opinion of the investigator and the sponsor makes it undesirable
             for the patient to participate in the trial. Screening for chronic conditions is not
             required.

         10. Known active hepatitis B virus (HBV). Note: Controlled (treated) hepatitis will be
             allowed if they meet the following criteria, antiviral therapy for HBV must be given
             for at least 1 month prior to first dose of study drug, and HBV viral load must be
             less than 2000 IU/ml (104 copies/ml) prior to the first dose of study drug. Those on
             active HBV therapy with viral loads under 2000 IU/ml (104 copies/ml) should stay on
             the same therapy throughout the study treatment (Appendix E).

         11. Known active hepatitis C virus (HCV). Note: Untreated patients with chronic infection
             by HCV are allowed on study. In addition, successfully treated patients (defined as
             sustained virologic response SVR12 or SVR24) are allowed, as long as there is 4 weeks
             between achieving sustained viral response (SVR12 or SVR24) and starting study drug.

         12. Known human immunodeficiency virus (HIV); excluded due to potential drug-drug
             interactions between anti-retroviral medications and LY3410738.

         13. Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or
             inducers (Appendix F) and/or P-gp inhibitors (Appendix G).

         14. Treatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738
             (Appendix H). For recommended alternatives, refer to Section 6.4.3.

         15. Clinically significant active malabsorption syndrome or other condition likely to
             affect gastrointestinal absorption of the study drug.

         16. Active second malignancy unless in remission and with life expectancy > 2 years. Refer
             to protocol exclusion criteria (Section 4.2) for examples of allowed second
             malignancies.

         17. Pregnancy, lactation or plans to breastfeed during the study or within 3 months of the
             last dose of study intervention.

         18. Patients with known hypersensitivity to any component of LY3410738 or its formulation.